Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Mind Medicine (MindMed) Inc. (MMED.NE)

NEO - NEO Real Time Price. Currency in CAD
Add to watchlist
7.83-0.60 (-7.12%)
At close: 03:58PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.43
Open7.88
Bid7.27 x N/A
Ask8.30 x N/A
Day's Range7.65 - 8.32
52 Week Range7.65 - 55.05
Volume27,983
Avg. Volume38,938
Market Cap240.023M
Beta (5Y Monthly)1.74
PE Ratio (TTM)N/A
EPS (TTM)-0.30
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for MMED.NE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • CNW Group

      MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

      Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the first patient has been dosed in a Phase 1 investigator-initiated study led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to evaluate the effects of MDMA-like substances, including MDA, Lys-MDMA, Lys-MDA, versus a placebo in healthy vo

    • CNW Group

      MindMed Announces Compliance with Nasdaq Listing Requirements

      Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it has received a letter from The Nasdaq Stock Market LLC advising the Company that it has regained compliance with Nasdaq's minimum bid price listing requirement. The Company has satisfied the terms for continued listing on the Nasdaq Capital Market by complying with the minimum bid pric

    • Market Exclusive

      Weekly Roundup on the Cannabis Sector & Psychedelic Sector

      Key Takeaways; Cannabis Sector Glass House Brands closed the acquisitions two California dispensaries. Cansortium’s Q2 revenue rose to $22.4 million; the company forecasts 42% growth in 2022. Key Takeaways; Psychedelic Sector Awakn’s technical analysis is growing stronger, according to a seasoned technical expert. MindMed announced positive results from a clinical trial for patients with anxiety; […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector appeared first on Market Exc

    Advertisement
    Advertisement